The DOI matches its Crossref record.
A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder
Abstract
The efficacy and tolerability of Lu AA21004 at 5 mg/day, a novel multimodal antidepressant, were assessed in elderly patients with recurrent major depressive disorder. Patients were randomly assigned (1:1:1) to Lu AA21004 5 mg/day, duloxetine 60 mg/day (reference) or to placebo in an 8-week double-blind study. The primary efficacy measure was the 24-item Hamilton Depression Scale (HAM-D(24)) total score (analysis of covariance, last observation carried forward). Patients (mean age 70.6 years) had a mean baseline HAM-D(24) score of 29.0. Lu AA21004 showed significantly (P = 0.0011) greater improvement on the primary efficacy endpoint compared with placebo at week 8 (3.3 points). Duloxetine also showed superiority to placebo at week 8, thereby validating the study. HAM-D(24) response (53.2 vs. 35.2%) and HAM-D(17) remission (29.2 vs. 19.3%) rates at endpoint were higher for Lu AA21004 than for placebo. Lu AA21004 showed superiority to placebo in cognition tests of speed of processing, verbal learning and memory. The withdrawal rate due to adverse events was 5.8% (Lu AA21004), 9.9% (duloxetine) and 2.8% (placebo). Whereas nausea was the only adverse event with a significantly higher incidence on treatment with Lu AA21004 (21.8%) compared with placebo (8.3%), the incidence of nausea, constipation, dry mouth, hyperhidrosis and somnolence was higher for duloxetine. In conclusion, Lu AA21004 was efficacious and well tolerated in the treatment of elderly patients with recurrent major depressive disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study by Katona et al. [7] in older patients with MDD found that vortioxetine and duloxetine had major effects on verbal learning and memory, compared with a placebo. Still, only vortioxetine significantly affected a test of processing speed and executive function.”
From Efficacy of Vortioxetine Versus Escitalopram on the Cognitive Profile of Patients With Depressive Disorder: A Comparative Study (2025) · cites this paper as [7]
In the citing paper
“Vortioxetine has previously demonstrated direct effects on objective measures of cognition in three large-scale, pivotal studies of depressed patients [7,8,20].”
From Efficacy of Vortioxetine Versus Escitalopram on the Cognitive Profile of Patients With Depressive Disorder: A Comparative Study (2025) · cites this paper as [7]
In the citing paper
“A series of industry-sponsored, double-blind, and randomized placebo-controlled clinical trials have shown the efficacy of the antidepressant vortioxetine on objective cognitive function, subjective CC, and depressive symptoms in MDD [27,28].”
In the citing paper
“In this study and two previous studies in patients with MDD, vortioxetine significantly improved cognitive performance (as measured by the change in DSST–number of correct symbols) (Katona et al, 2012; McIntyre et al, 2014), with a Cohen's d effect size ranging from 0.25 to 0.48 across all three studies.”
From A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder (2015) · cites this paper as Katona et al, 2012
In the citing paper
“Clinical evidence from a double-blind, placebo-controlled, duloxetine-referenced study in elderly (≥65 years old) MDD patients demonstrated superiority for vortioxetine compared with placebo in predefined objective neuropsychological tests of speed of processing, verbal learning, and memory (Katona et al, 2012).”
From A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder (2015) · cites this paper as Katona et al, 2012
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Cognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
Jaeger, J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000941 · Cited by 836
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Self-citationBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“Data from new antidepressant agents studied in elderly patients (Katona et al. 2012) have to be substantiated.”
Background
Metadata
- Authors
- Katona, C., Hansen, T., & Olsen, C. K.
- Affiliations
- University College London (GB)
- Lundbeck (Denmark) (DK)
- Corresponding author
- Katona, Cornelius
- ORCID
- Katona, Cornelius
- Venue
- International Clinical Psychopharmacology
- Published
- 2012-07
- Volume
- 27
- Issue
- 4
- Pages
- 215-223
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2011606125
- Semantic Scholar
- 5f172e5e5c890ffe428add089a4943c3a2a1c42c
- Cited by
- 445
- References
- 0
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 23 · 2023: 26 · 2022: 17 · 2021: 21 · 2020: 49 · 2019: 35 · 2018: 21 · 2017: 41 · 2016: 47 · 2015: 71 · 2014: 36 · 2013: 20 · 2012: 7
- FWCI
- 31.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- vortioxetine, major depressive disorder, elderly patients, recurrent depression, duloxetine, multimodal antidepressant, antidepressant efficacy, antidepressant safety, adverse events, nausea, cognitive function, remission, placebo comparison
- MeSH terms
- Duloxetine Hydrochloride, Vortioxetine, Aged, Aged, 80 and over, Antidepressive Agents, Cognition Disorders, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Piperazines, Placebos, Psychiatric Status Rating Scales, Sulfides, Thiophenes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. https://app.cochat.ai/papers/10.1097/yic.0b013e3283542457
- The paper
- Katona, C., Hansen, T., & Olsen, C. K. (2012). A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e3283542457
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.